Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01908114
Other study ID # 2432-PED-ERC-12
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date July 2013
Est. completion date December 2021

Study information

Verified date February 2021
Source Aga Khan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the projects is to Develop and implement a Package of interventions that will comprise of an augmented communication and counseling strategy coupled with private sector involvement and a combined Oral Polio Vaccine and Inject able Polio Vaccine approach during the Polio campaigns followed by the evaluation of this project for acceptability, feasibility and effectiveness of the intervention Package.


Description:

This particular project has been designed to address the bottlenecks through innovations to address community mobilization and demand creation on one hand and assess the synergistic immune enhancement potential of combining Inject able Polio Vaccine (IPV) and Oral Polio Vaccine (OPV) in at-risk children. This project will be implemented in high risk union councils of Karachi, district Kashmore in Sindh and Bajaur Agency in Federally administered Tribal areas (FATA) This will be a three cell cluster randomized trial to achieve the objectives of the study. The first cell of the study will receive all the routine activities being carried out by the polio program, the second cell will receive an expanded intervention with community support groups, enhanced communication package, education and counseling and involvement of private sector. While the third cell will receive all of the interventions of second cell with a combined OPV IPV approach during the polio immunization campaign through child health camps. We have calculated a total sample size of 120 clusters, 40 clusters per group for each study area i-e 120 for Karachi, 120 for Kashmore and 120 for Bajaur. Polio program in Pakistan has well established and demarcated vaccination areas assigned to a vaccination team, each vaccination area usually covers about 200 children therefore the area of vaccination team will be considered as one cluster in the proposed study. The implementation of the project will be followed by impact assessment activities that will include post vaccination coverage surveys and Immunity assessment activities and Environmental sample collection. A total sample size of 5310 children has been calculated for the immunity studies for seroprevalance and 5130 for stool virus shedding


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60000
Est. completion date December 2021
Est. primary completion date July 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Month to 5 Years
Eligibility Inclusion Criteria: - Healthy children aged 1 month to 5 years that reside within the study sites, and do not plan to travel away during entire the study period. Exclusion Criteria: - Children with known thrombocytopenia or bleeding disorders; children acutely ill or with signs of acute infection (e.g. fever = 101 F) at the time of NID and a diagnosis or suspicion of immunodeficiency disorder.

Study Design


Intervention

Behavioral:
Enhanced Community mobilization

Biological:
Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA


Locations

Country Name City State
Pakistan Aga Khan University Karachi Sindh

Sponsors (8)

Lead Sponsor Collaborator
Aga Khan University Bill and Melinda Gates Foundation, National Institutes of Health, Pakistan, Pakistan Ministry of Health, Peshawar Medical College, Trust for Vaccines and Immunization, Pakistan, UNICEF, World Health Organization

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improved immunization coverage Improved coverage in both routine immunization and polio campaign Immunization compared to Baseline At the completion of all recruitment and follow ups which will take an average time of 1 year
Secondary Improved Polio Sero prevalence Population bases Immunity level for polio antibodies will be assessed by
Sero prevalance and conversion at various time points
The immunity levels will be assessed at the time of recruitment, six weeks after recruitment and 18 weeks after recruitment
Secondary Quantification of Polio virus in stool samples Quantification of Polio virus will be assessed in stool samples collected at day 28, day 35 and day 49 after recruitment The stool samples will be collected and analysed at day 28, day 35 and day 49 after recruitment
Secondary Shedding of Polio virus in stool samples Shedding of Polio virus in stool samples will be assessed at day day 28, day 35 and day 49 after recruitment The stool samples will be collected and analysed at day 28, day 35 and day 49 after recruitment
See also
  Status Clinical Trial Phase
Completed NCT00772369 - Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Phase 4
Completed NCT00401531 - Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants Phase 3
Completed NCT00772928 - Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™ Phase 3
Completed NCT00254917 - Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Phase 4
Completed NCT04576910 - Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China Phase 4
Completed NCT04264546 - Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib) Phase 1/Phase 2
Not yet recruiting NCT06114810 - Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV Phase 4
Completed NCT01475539 - Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine Phase 4
Completed NCT01244464 - A Study of the Safety of IMOVAX Polio™ in China Phase 4
Completed NCT00255047 - Safety and Immune Response of Different Pediatric Combination Vaccines. Phase 3
Recruiting NCT05850364 - A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine Phase 3
Completed NCT00662870 - Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine Phase 3
Completed NCT03147560 - Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants Phase 4
Completed NCT05083039 - Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Active, not recruiting NCT00932269 - Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease Phase 0
Completed NCT03922061 - Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant Phase 1
Enrolling by invitation NCT03818477 - Environmental Surveillance (ES) for Polio and AMR Using the TaqMan Array Card
Completed NCT00348387 - Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV Phase 3
Not yet recruiting NCT06460545 - Phase IV Study of Concomitant Administration of the sIPV and HepA Phase 4
Completed NCT01389687 - Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan Phase 3